Pfizer Inc. — 2010 Form 10-K
Reporting period: Fiscal year ended December 31, 2010. Although the request metadata says “2010 Q4,” this is an annual filing, not a standalone fourth-quarter report. Pfizer is a global biopharmaceutical company with Biopharmaceutical and Diversified segments. The acquisition of Wyeth closed in October 2009, so 2010 includes a full year of Wyeth operations.
Financial performance and key metrics
| Metric | 2010 filing disclosures |
|---|---|
| Biopharmaceutical revenue | $58.5 billion, up 29% from 2009. The inclusion of legacy Wyeth products contributed approximately $13.7 billion; foreign exchange contributed approximately $900 million. Legacy Pfizer product revenues declined approximately $1.5 billion. |
| Diversified revenue | Up 114% from 2009, chiefly reflecting approximately $4.4 billion of legacy Wyeth revenues. Legacy Pfizer Diversified operations grew 3%; foreign exchange contributed 5%. |
| International revenue | $38.8 billion, or 57% of total revenue. The U.S. accounted for 43% of total revenue. |
| Research and development | $9.4 billion, compared with $7.8 billion in 2009 and $7.9 billion in 2008. |
| Consumer Healthcare, Nutrition and Capsugel | 2010 revenues were $2.8 billion, $1.9 billion and $752 million, respectively. |
| Profit, cash flow, margins, debt and liquidity | The supplied filing text does not provide clear consolidated values for these metrics; it refers readers to the incorporated 2010 Financial Report. Management stated that it did not anticipate a material liquidity impact from economic conditions and cited operating cash flow, financial assets, capital-market access and credit facilities. |
Changes versus the prior comparable period
- Biopharmaceutical growth primarily reflects the full-year inclusion of Wyeth, partly offset by lower revenues from legacy Pfizer products, including Lipitor, Norvasc and Camptosar.
- Legacy Pfizer Biopharmaceutical revenues faced generic competition and loss of exclusivity in certain markets. U.S. healthcare legislation also increased rebates; the filing cites a $664 million unfavorable U.S. impact in 2010.
- Diversified revenue more than doubled, primarily because Wyeth added Consumer Healthcare and Nutrition operations. Animal Health revenue rose 29%, including Wyeth contributions, legacy Pfizer growth and favorable currency effects.
- Foreign exchange generally benefited 2010 revenue and net income, though the filing text does not provide a clear consolidated dollar amount for the net-income impact.
Outlook, risks and unusual items
- In February 2011, Pfizer announced it would concentrate R&D on immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines. It expected significant reductions in annual R&D expense; no quantified savings or earnings guidance is provided in the supplied text.
- Management anticipated continuing pricing pressure, especially in Europe, and identified the U.S. Affordable Care Act’s rebates, discounts and fees as costs expected to affect future expenses and profitability.
- Loss of exclusivity is a significant risk. Pfizer expected U.S. Lipitor exclusivity to end in November 2011, with substantial sales erosion thereafter; it also cited upcoming or recent exclusivity losses for products including Xalatan, Caduet and Aricept, and generic competition for Effexor XR.
- Other material risks include patent challenges, product safety or regulatory actions, clinical-development failures, biosimilar competition, foreign-exchange exposure, government price controls, litigation and successful integration of Wyeth.
- Pfizer agreed to acquire King Pharmaceuticals for $3.6 billion in cash. It acquired approximately 92.5% of King in a January 2011 tender offer and planned to complete the merger in February 2011.
- Pfizer reported $48.7 million in environmental capital expenditures and $184.8 million in other environmental expenses for 2010. It was reviewing strategic alternatives for Capsugel, potentially including a divestiture.
- In February 2011, Pfizer announced a new $5 billion share-purchase authorization, bringing total current authorization to $9 billion, and anticipated $5 billion of repurchases in 2011.
Important facts for investors to verify
- Consult the incorporated 2010 Financial Report for consolidated revenue, net income, margins, cash flows, debt, liquidity, segment profit and full-year versus quarterly comparisons; the supplied text does not give clear values for these.
- Assess the expected timing and magnitude of Lipitor and other product revenue losses from generic entry and patent outcomes.
- Verify the realized R&D savings, restructuring costs and pipeline progress following the announced research refocus.
- Review the final King acquisition terms and integration results, along with the costs and benefits of Wyeth integration.
- Monitor the financial effects of healthcare reform, international pricing actions, foreign exchange, litigation and other contingencies.